COVID-19 Results Briefing

Pakistan

January 28, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in Pakistan. The model was run on January 27, 2021 with data through January 25, 2021.

Current situation

- Daily reported cases in the last week decreased to about 2,100 per day on average compared to about 2,400 the week before (Figure 1).
- Daily deaths in the last week was about 50 per day on average (Figure 2). This makes COVID-19 the number 22 cause of death in Pakistan this week (Table 1).
- Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 2 provinces (Figure 3).
- We estimated that 3% of people in Pakistan have been infected as of January 25 (Figure 4).
- No locations had daily death rates greater than 4 per million (Figure 5).

Trends in drivers of transmission

- In the last week, no new mandates have been imposed. No mandates have been lifted this week (Table 2).
- Mobility last week was 2% lower than the pre-COVID-19 baseline (Figure 7). Mobility was near baseline (within 10%) in Azad Jammu & Kashmir, Balochistan, Gilgit-Baltistan, Khyber Pakhtunkhwa, Punjab, and Sindh.
- As of January 25 we estimated that 52% of people always wore a mask when leaving their home (Figure 8).
- There were 16 diagnostic tests per 100,000 people on January 25 (Figure 9).
- The fraction of the population who are open to receiving a COVID-19 vaccine ranges from 84% in Punjab to 85% in Islamabad Capital Territory (Figure 10).
- About 14.09 million are expected to be vaccinated by May 1 (Figure 12). With faster scale-up, the number vaccinated could reach about 22.9 million.
Projections

- In our **reference scenario**, which represents what we think is most likely to happen, our model projects about 15,000 cumulative deaths on May 1, 2021. This represents about 4,000 additional deaths from January 25 to May 1 (Figure 13). Daily deaths has peaked at 50 on January 4, 2021 (Figure 14).

- If **universal mask coverage (95%)** were attained in the next week, our model projects about 1,000 fewer cumulative deaths compared to the reference scenario on May 1, 2021.

- We estimate that 6.2% of people will be immune on May 1, 2021 (Figure 16).

- The reference scenario assumes that 0 provinces will re-impose mandates by May 1, 2021 (Figure 17).

- Figure 20 compares our reference scenario forecasts to other publicly archived models. Forecasts are widely divergent.

- 5 provinces will have high or extreme stress on hospital beds at some point in December through May (Figure 21). 7 provinces will have high or extreme stress on ICU capacity in December through May (Figure 22).

Model updates

In order to capture the impact of variants and the potential impact of further spread of new variants, we have made changes to our scenarios. We now show results for four scenarios when projecting COVID-19.

The **reference scenario** is our forecast of what we think is most likely to happen and makes the following assumptions: 1) Vaccines will continue to be distributed at the expected pace. 2) Governments adapt their response by re-imposing social distancing mandates for six weeks whenever daily deaths reach eight per million, unless a location has already spent at least seven of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates, in which case mandates are re-imposed when daily deaths reach 15 per million. 3) Variant B.1.1.7 (first identified in the UK) continues to spread in locations where 100 or more isolates have been detected to date. 4) Mask use stays at current levels.

The **rapid variant spread scenario** shares assumptions with the reference scenario and in addition, we assume that variant B.1.351 (first identified in South Africa) spreads to everywhere in the world, starting February 1, 2021. Variant B.1.351 spreads at the observed rate that B.1.1.7 spread in London. The variant is assumed to increase the infection-fatality ratio by 29% and transmissibility by 35%. This scenario also assumes that those vaccinated are less effectively protected against variant B.1.351: Pfizer, Moderna, Janssen, and Novavax clinical effectiveness is reduced by 20%; all other vaccines’ clinical effectiveness is reduced by 50%.

The **worst case scenario** makes the same assumptions as the rapid variant spread scenario and also assumes that mobility moves towards pre-COVID-19 levels as vaccination rates increase.
The universal masks scenario makes all the same assumptions as the reference scenario and also assumes 95% mask usage adopted in public in every location.

In summary, here are the assumptions in each of the four scenarios:

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Mobility</th>
<th>New variant spread</th>
<th>Vaccination</th>
<th>Mask use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference (most likely to happen)</td>
<td>Mobility in the unvaccinated follows the pattern seen last year associated with seasonality. In 25% of those vaccinated, mobility returns toward pre-COVID-19 levels.</td>
<td>B.1.1.7 (UK) continues to spread in locations with &gt; 100 cases detected.</td>
<td>Expected pace</td>
<td>Stays at current levels</td>
</tr>
</tbody>
</table>
| Rapid variant increase | Mobility in the unvaccinated follows the pattern seen last year associated with seasonality. In 25% of those vaccinated, mobility returns toward pre-COVID-19 levels. | • B.1.1.7 (UK) continues to spread in locations with > 100 cases detected.  
  • B.1.351 (S. Africa) spreads everywhere in the world starting Feb 1. | • Expected pace  
  • Vaccines’ effectiveness lower against B.1.351 | Stays at current levels |
| Worst case             | Mobility in the unvaccinated follows the pattern seen last year associated with seasonality. In 100% of those vaccinated, mobility returns toward pre-COVID-19 levels. | • B.1.1.7 (UK) continues to spread in locations with > 100 cases detected.  
  • B.1.351 (S. Africa) spreads everywhere in the world starting Feb 1. | • Expected pace  
  • Vaccines’ effectiveness is lower against B.1.351 | Stays at current levels |
| Universal mask use     | Mobility in the unvaccinated follows the pattern seen last year associated with seasonality. In 25% of those vaccinated, mobility returns towards pre-COVID-19 levels. | B.1.1.7 (UK) continues to spread in locations with >100 cases detected. | Expected pace        | Increases to 95%        |

*Note that scenarios assume the following about social-distancing mandates. Governments adapt their response by re-imposing social distancing mandates for six weeks whenever daily deaths reach eight per million, unless a location has already spent at least seven of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates, in which case mandates are re-imposed when daily deaths reach 15 per million.*
More details on each of the assumptions

•  **How do the new variants scale up over time?**

In locations with more than 100 B.1.1.7 variants sequenced, we have included the further scale-up of the variant. Based on studies reported in England, we assume that B.1.1.7 is 35% more transmissible and the infection-fatality ratio is 29% higher than wild variants.

For B.1.351, we assume that the scale-up of the proportion of cases due to the new variant will follow the trajectory that has been well documented in London and other English locations for B.1.1.7. We assume that the variant is 35% more transmissible and the infection-fatality ratio is 29% higher. In the rapid variant scenario and the worst case scenario, we assume that B.1.351 will be introduced in all locations on February 1. With our assumptions of infectiousness, we find that all locations reach 80% of infections due to B.1.351 by May 19.

•  **How effective are the vaccines against the new variants?**

This scenario assumes that those vaccinated are less effectively protected against variant B.1.351: Pfizer, Moderna, Janssen, and Novavax clinical effectiveness is reduced by 20%; all other vaccines clinical effectiveness is reduced by 50%.

•  **How do we forecast increases in mobility in the worst case scenario?**

We have modified our mobility forecasts to reflect that as the coverage of vaccination increases, there will likely be fewer mandates in place. We reflect this in our model that forecasts mandates by building in an assumption that as vaccine coverage increases, the probability that mandates will stay in place decreases. Specifically, we do this by applying a scalar that ranges from 1 when vaccine coverage a month ago was zero to 0.5 when vaccine coverage a month ago was 75%. This scalar is multiplied by the location-specific projections of the percent of mandates that are in place. As data emerges in places with high levels of vaccination, we will modify this assumption in future iterations of the model.
Current situation

Figure 1. Reported daily COVID-19 cases
Table 1. Ranking of COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Weekly deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonatal disorders</td>
<td>4,804</td>
<td>1</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>3,527</td>
<td>2</td>
</tr>
<tr>
<td>Stroke</td>
<td>2,028</td>
<td>3</td>
</tr>
<tr>
<td>Diarrheal diseases</td>
<td>1,481</td>
<td>4</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>1,311</td>
<td>5</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>1,207</td>
<td>6</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>1,205</td>
<td>7</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>917</td>
<td>8</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>854</td>
<td>9</td>
</tr>
<tr>
<td>Cirrhosis and other chronic liver diseases</td>
<td>848</td>
<td>10</td>
</tr>
<tr>
<td>COVID-19</td>
<td>324</td>
<td>22</td>
</tr>
</tbody>
</table>

Figure 2a. Reported daily COVID-19 deaths
Figure 2b. Estimated cumulative deaths by age group

Figure 3. Mean effective R on January 14, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.
Figure 4. Estimated percent of the population infected with COVID-19 on January 25, 2021
Figure 5. Daily COVID-19 death rate per 1 million on January 25, 2021
Critical drivers

Table 2. Current mandate implementation

*Not all locations are measured at the subnational level.
Figure 6. Total number of social distancing mandates (including mask use)
Figure 7a. Trend in mobility as measured through smartphone app use compared to January 2020 baseline

Figure 7b. Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on January 25, 2021
Figure 8a. Trend in the proportion of the population reporting always wearing a mask when leaving home on January 25, 2021

Figure 8b. Proportion of the population reporting always wearing a mask when leaving home on January 25, 2021
**Figure 9a.** Trend in COVID-19 diagnostic tests per 100,000 people

**Figure 9b.** COVID-19 diagnostic tests per 100,000 people on January 20, 2021
Figure 10. Increase in the risk of death due to pneumonia on February 1 2020 compared to August 1 2020.
**Figure 11.** This figure shows the estimated proportion of the adult (18+) population that is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and unsure).

![Figure 11.](image)

**Figure 12.** The number of people who receive any vaccine and those that are immune accounting for efficacy, loss to follow up for two-dose vaccines, and a 28 day delay between first dose and immunity for two-dose vaccines.

![Figure 12.](image)
Projections and scenarios

We produce four scenarios when projecting COVID-19. The reference scenario is our forecast of what we think is most likely to happen. Vaccines are distributed at the expected pace. Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates, in which case mandates are re-imposed when daily deaths reach 15 per million. Variant B.1.1.7 (first identified in the UK) continues to spread in locations where 100 or more isolates have been detected to date.

The rapid variant spread scenario shares assumptions with reference but variant B.1.351 (first identified in South Africa) spreads to everywhere in the world, starting Feb. 1, 2021. Variant B.1.351 spreads at the observed rate that B.1.1.7 spread in London. The variant is assumed to increase the infection-fatality rate by 29% and transmissibility by 25%. This scenario also assumes that those vaccinated are less effectively protected against variant B.1.351: Pfizer, Moderna, Janssen, and Novavax clinical effectiveness is reduced by 20%; all other vaccines clinical effectiveness is reduced by 50%. Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates, in which case mandates are re-imposed when daily deaths reach 15 per million. Variant B.1.1.7 (first identified in the UK) continues to spread in locations where 100 or more isolates have been detected to date.

The worst case scenario makes the same assumptions as the rapid variant spread scenario but also assumed that in those that are vaccinated mobility moves towards pre-COVID-19 levels.

The universal masks scenario makes all the same assumptions as the reference scenario but also assumes 95% mask usage adopted in public in every location.
Figure 13. Cumulative COVID-19 deaths until May 01, 2021 for four scenarios
**Figure 14.** Daily COVID-19 deaths until May 01, 2021 for four scenarios
Figure 15. Daily COVID-19 infections until May 01, 2021 for four scenarios
Figure 16. Estimated percentage immune based on cumulative infections and vaccinations. We assume that vaccine impact on transmission is 50% of the vaccine effectiveness for severe disease.
Figure 17. Month of assumed mandate re-implementation. We assume that governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates, in which case mandates are assumed to be re-imposed when daily deaths reach 15 per million.
Figure 18. Forecasted percent infected with COVID-19 on May 01, 2021

Figure 19. Daily COVID-19 deaths per million forecasted on May 01, 2021 in the reference scenario
**Figure 20.** Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology (Delphi; https://www.covidanalytics.io/home), Imperial College London (Imperial; https://www.covidsim.org), The Los Alamos National Laboratory (LANL; https://covid-19.bsvgateway.org/), and the SI-KJalpha model from the University of Southern California (SIKJalpha; https://github.com/scc-usc/ReCOVER-COVID-19). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.
Figure 21. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered low stress, 5-9% is considered moderate stress, 10-19% is considered high stress, and greater than 20% is considered extreme stress.
**Figure 22.** The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered *low stress*, 10-29% is considered *moderate stress*, 30-59% is considered *high stress*, and greater than 60% is considered *extreme stress.*
Table 3. Ranking of COVID-19 among the leading causes of mortality in the full year 2020. Deaths from COVID-19 are projections of cumulative deaths on Jan 1, 2021 from the reference scenario. Deaths from other causes are from the Global Burden of Disease study 2019 (rounded to the nearest 100).

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Annual deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonatal disorders</td>
<td>249,800</td>
<td>1</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>183,400</td>
<td>2</td>
</tr>
<tr>
<td>Stroke</td>
<td>105,400</td>
<td>3</td>
</tr>
<tr>
<td>Diarrheal diseases</td>
<td>77,000</td>
<td>4</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>68,200</td>
<td>5</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>62,800</td>
<td>6</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>62,700</td>
<td>7</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>47,700</td>
<td>8</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>44,400</td>
<td>9</td>
</tr>
<tr>
<td>Cirrhosis and other chronic liver diseases</td>
<td>44,100</td>
<td>10</td>
</tr>
<tr>
<td>COVID-19</td>
<td>10,194</td>
<td>26</td>
</tr>
</tbody>
</table>
More information

Data sources:

Mask use data sources include PREMISE; Facebook Global symptom survey (This research is based on survey results from University of Maryland Social Data Science Center) and the Facebook United States symptom survey (in collaboration with Carnegie Mellon University); Kaiser Family Foundation; YouGov COVID-19 Behaviour Tracker survey.

Vaccine hesitancy data are from the COVID-19 Beliefs, Behaviors, and Norms Study, a survey conducted on Facebook by the Massachusetts Institute of Technology (https://covidsurvey.mit.edu/).

Data on vaccine candidates, stages of development, manufacturing capacity, and pre-purchasing agreements are primarily from Linksbridge and supplemented by Duke University.

A note of thanks:

We wish to warmly acknowledge the support of these and others who have made our covid-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.